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abstract
PURPOSE Phosphatidylinositol 3-kinase (PI3K) signaling is highly active in glioblastomas. We assessed phar-
macokinetics, pharmacodynamics, and efﬁcacy of the pan-PI3K inhibitor buparlisib in patients with recurrent
glioblastoma with PI3K pathway activation.
METHODS This study was a multicenter, open-label, multi-arm, phase II trial in patients with PI3K pathway–
activated glioblastoma at ﬁrst or second recurrence. In cohort 1, patients scheduled for re-operation after
progression received buparlisib for 7 to 13 days before surgery to evaluate brain penetration and modulation of
the PI3K pathway in resected tumor tissue. In cohort 2, patients not eligible for re-operation received buparlisib
until progression or unacceptable toxicity. Once daily oral buparlisib 100 mg was administered on a continuous
28-day schedule. Primary end points were PI3K pathway inhibition in tumor tissue and buparlisib pharma-
cokinetics in cohort 1 and 6-month progression-free survival (PFS6) in cohort 2.
RESULTS Sixty-ﬁve patients were treated (cohort 1, n = 15; cohort 2, n = 50). In cohort 1, reduction of
phosphorylated AKTS473 immunohistochemistry score was achieved in six (42.8%) of 14 patients, but effects on
phosphoribosomal protein S6S235/236 and proliferation were not signiﬁcant. Tumor-to-plasma drug level was 1.0.
In cohort 2, four (8%) of 50 patients reached 6-month PFS6, and the median PFS was 1.7 months (95% CI, 1.4
to 1.8 months). The most common grade 3 or greater adverse events related to treatment were lipase elevation
(n = 7 [10.8%]), fatigue (n = 4 [6.2%]), hyperglycemia (n = 3 [4.6%]), and elevated ALT (n = 3 [4.6%]).
CONCLUSION Buparlisib had minimal single-agent efﬁcacy in patients with PI3K-activated recurrent glioblas-
toma. Although buparlisib achieved signiﬁcant brain penetration, the lack of clinical efﬁcacy was explained by
incomplete blockade of the PI3K pathway in tumor tissue. Integrative results suggest that additional study of
PI3K inhibitors that achieve more-complete pathway inhibition may still be warranted.
J Clin Oncol 37:741-750. © 2019 by American Society of Clinical Oncology
INTRODUCTION
Glioblastoma is the most common malignant primary
brain tumor.1 Despite treatment with surgery, radiation
therapy (RT), and chemotherapy, outcomes have not
substantially improved over the past two decades, with
median overall survival (OS) of only 14 to 18months.2-4
Limited drug delivery as a result of the blood-brain
barrier (BBB) represents one of the most signiﬁcant
challenges and partly explains why many agents
that target oncogenic pathways of glioblastoma but
whose chemical properties do not allow signiﬁcant
BBB penetration have minimal efﬁcacy.5 However,
few studies directly examined tumor tissue during
treatment,6,7 which prevents reliable conclusions
about drug effectiveness with regard to level of target
inhibition and effects on cell death and proliferation.
Studies designed to conﬁrm drug penetration and
target engagement therefore may be critical to un-
derstanding trial results and improving outcomes in
glioblastoma.
The PI3K pathway is activated in most glioblastomas.8
PTEN loss and PIK3CA or PIK3R1mutations represent
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potential therapeutic targets that are found in approxi-
mately 45% of glioblastomas.8,9 Previous trials of mecha-
nistic target of rapamycin (mTOR) complex 1 inhibitors did
not show signiﬁcant efﬁcacy.6,10,11 More recently, PI3K
inhibitors have been evaluated. In a trial of the pan-PI3K
inhibitor PX-866 in 32 molecularly unselected patients with
recurrent glioblastoma, one patient achieved a partial re-
sponse (PR), and the 6-month progression-free survival
(PFS6) rate was 17%.12 However, this study did not
evaluate whether adequate brain penetration and target
engagement was achieved.
Buparlisib (NVP-BKM120) is an oral pan-PI3K inhibitor that
targets all four isoforms of class 1 PI3K (a, b, g, and d).13
Buparlisib has high penetration across the BBB. In pre-
clinical studies, buparlisib enters the brain at therapeutic
concentrations demonstrated to inhibit the PI3K pathway in
normal brain and gliomamodels in vitro and in vivo.14-16 The
Ivy Foundation Early Phase Clinical Trials Consortium
conducted a phase II trial of buparlisib in patients with
recurrent glioblastoma with evidence of PI3K pathway
activation to assess the pharmacokinetics, pharmacody-
namics, and efﬁcacy of buparlisib in this population.
METHODS
Study Design and Participants
This study was a multicenter, open-label, and multi-arm
phase II trial in patients with recurrent glioblastoma at ﬁrst
or second relapse. Written informed consent was obtained
from all participants. The study was approved by the local
institutional review board of each participating institution
and consisted of two cohorts: a surgery plus treatment arm
(cohort 1) and a treatment-only arm (cohort 2; Appendix Fig
A1, online only). Eligible participants were age 18 years or
older with a centrally conﬁrmed diagnosis of glioblastoma.
Patients must have not responded to prior RT, with an
interval of at least 12 weeks from RT completion to study
entry. Tumor progression was conﬁrmed by magnetic
resonance imaging or computed tomography scan. Prior
treatment with bevacizumab or vascular endothelial growth
Patients screened for eligibility
(n = 136)
Eligible
(n = 65)
Assigned to cohort 1
Did not receive treatment
Assigned to cohort 2
Did not receive treatment
Received buparlisib plus surgery
Discontinued treatment
   Disease progression
   Adverse event
   Physician decision
   Lost to follow-up or other reason
Received buparlisib
Discontinued treatment
   Disease progression
   Adverse event
   Physician decision
   Lost to follow-up or other reason
Included in the safety analysis
Included in the PK/PD analysis
   Central pathological review
   Evaluable for PK and PD
   Molecular diagnostic testing
Included in the safety analysis
Included in the PFS6 analysis
Included in the biomarker analysis
   Central pathological review
   Molecular diagnostic testing
Excluded
   Pathologically ineligible
   Withdraw from screening
   Laboratory findings or active infection
   Clinical deterioration
   Progressive disease not confirmed
   Other reason
(n = 71)
(n = 36)
(n = 15)
(n = 11)
(n = 2)
(n = 2)
(n = 5)
(n = 15)
(n = 15)
(n = 15)
(n = 15)
(n = 15)
(n = 14)
(n = 8)
(n = 50)
(n = 50)
(n = 50)
(n = 50)
(n = 38)
(n = 15) (n = 50)
(n = 13) (n = 46)
(n = 1) (n = 1)
(n = 1) (n = 0)
(n = 0) (n = 3)
(n = 50)
(n = 50)
(n = 0)(n = 0)
FIG 1. Study ﬂow. PD, pharmacodynamics;
PFS6, 6-month progression free survival;
PK, pharmacokinetics.
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factor receptor44 inhibitors, PI3K, AKT, or mTOR inhibitors
was not permitted. Patients had a Karnofsky performance
status greater than or equal to 60, adequate organ and
bone marrow function, fasting plasma glucose less than
120 mg/dL, hemoglobin A1C less than or equal to 8%,
baseline left ventricular ejection fraction greater than or
equal to 50%, and QTc less than 480 ms. Patients on
enzyme-inducing anticonvulsants, warfarin, more than
4 mg/d dexamethasone, strong CYP3A inhibitors or inducers,
or QT-prolonging medications were excluded, as were
patients with a history of clinically signiﬁcant cardiovascular
events, intratumoral hemorrhage, or psychiatric disorders.
Histomolecular criteria for eligibility included PIK3CA or
PIK3R1 mutation, loss of PTEN activity through PTEN
mutation, homozygous deletion or negative PTEN expres-
sion (, 10% of tumor cells that stained positive), or positive
phosphorylated AKTS473 (pAKTS473) by central immuno-
histochemistry (IHC) review. Cohort 1 surgical patients were
required to have positive expression of pAKTS473 within the
archival tumor.
Procedure
Buparlisib was supplied by Novartis (East Hanover, NJ).
The dose of buparlisib was 100 mg administered orally
daily.17,18
In cohort 1, participants received a pre-operative course of
buparlisib for 7 to 13 days. The last dose of buparlisib was
on the day of surgery. Whenever possible, tissue from both
enhancing and nonenhancing tumor was collected. After
recovery from surgery, participants resumed buparlisib in a
manner consistent with cohort 2. In cohort 2, participants
received buparlisib 100mg daily for each 28-day cycle until
disease progression or unacceptable toxicity.
Tumor assessments were performed with magnetic reso-
nance imaging scans every 8 weeks using the Response
Assessment in Neuro-Oncology criteria (Appendix Table A1,
online only).19 PFS6 was deﬁned as the proportion of par-
ticipants alive and progression free at 6-months from cycle 1,
day 1, of buparlisib. Only participants who had measurable
disease at baseline and received at least one dose of therapy
were evaluable for response, which was centrally reviewed for
participants who achieved response or PFS6. Adverse events
were evaluated using the National Cancer Institute Common
Terminology Criteria for Adverse Events (version 4.0). Addi-
tional analyses, including pharmacokinetics and IHC studies,
tumor genomic proﬁling, reverse-phase protein array (RPPA),
and matrix-assisted laser desorption/ionization-mass spec-
trometry imaging are described in the Appendix (online only).
Outcomes
The primary objectives in cohort 1 were to evaluate PI3K
pathway modulation as a result of buparlisib in tumor tissue
and to evaluate buparlisib concentration in enhancing and
nonenhancing tumor tissue and plasma. Secondary end
points included pharmacokinetics and safety of buparlisib
in this population. Exploratory end points included corre-
lation of 18F-ﬂuorodeoxyglucose (FDG) positron emission
tomography with response.
In cohort 2, the primary objective was to investigate the
treatment efﬁcacy of buparlisib in participants with re-
current glioblastoma as assessed by PFS6. Secondary end
points were response rates and the median PFS, OS, and
safety proﬁle of buparlisib. Exploratory end points included
correlation of outcomes with tumor genomics.
Sample Size Justiﬁcation
The cohort 1 primary end point was the modulation of the
PI3K pathway as assessed by IHC for pAKTS473 and
phosphorylated S6 S235/236 (pS6S235/236). On the basis of
historical data or mTOR complex 1 inhibitors in recurrent
glioblastoma,6 a pharmacodynamic response rate less than
40% was considered to be low, a response rate of greater
than or equal to 75% was considered to be high, and this
portion of the trial was considered a success if nine (60%)
of 15 participants showed a pathologic response. With a
sample size of 15 patients, there was a 94% chance of this
occurring if the true response rate was 75% and a 10%
chance of this occurring if the true response rate was 40%.
The cohort 2 primary end point was PFS6. Historical
comparison data suggested that ineffective therapies in
TABLE 1. Baseline Patient Demographics and Clinical Characteristics
Cohort, No. (%)
Characteristic 1 2
No. of patients 15 50
Median age, years (range) 55 (39-68) 56 (29-80)
Sex
Male 11 (73.3) 37 (74.0)
Female 4 (26.7) 13 (26.0)
KPS
100 2 (13.3) 9 (18.0)
90 10 (66.7) 23 (46.0)
80 2 (13.3) 15 (30.0)
70 1 (6.7) 3 (6.0)
Corticosteroids at baseline
Yes 7 (46.67) 24 (48.0)
No 8 (53.33) 26 (52.0)
Histology*
GBM, IDH1/2 wild type 13 (86.7) 37 (74.0)
GBM, IDH1/2 mutant 1 (6.7) 11 (22.0)
GBM, NOS 1 (6.7) 2 (4.0)
Median No. of prior systemic therapies (range) 1 (1-2) 1 (1-2)
Prior bevacizumab 0 (0) 0 (0)
Abbreviations: GBM, glioblastoma; KPS, Karnofsky performance status; NOS,
not otherwise speciﬁed.
*Diagnosis according to WHO 2016 diagnostic criteria.
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recurrent glioblastoma have a PFS6 rate of approximately
9% to 16%.5,20,21 The trial was sized to differentiate between
a 15% and a 32% PFS6. With a total sample size of 50
participants, this design yielded at least 90% power with a
one-sided a less than .1 to detect a true PFS6 rate of at least
32%. If the number of successes was 12 or more, the
therapy was to be considered worthy of additional study.
More statistical analysis details are provided in the Appendix.
RESULTS
Patient Characteristics
Between May 9, 2011, and February 26, 2014, 136 pa-
tients were screened for eligibility from seven centers in the
United States. Of these patients, 71 were excluded (Fig 1).
Sixty-ﬁve patients were eligible and assigned to receive
buparlisib (cohort 1, n = 15; cohort 2, n = 50; Fig 1).
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FIG 2. Buparlisib pharmacokinetics and phosphatidylinositol 3-kinase pathwaymodulation as a result of buparlisib in tumor tissue in cohort 1. (A) Box plots of
buparlisib concentration in non–contrast-enhancing (NCE) and contrast-enhancing (CE) tumor tissue assessed by liquid chromatography-tandem mass
spectrometry. Difference between groups was calculated using the Mann-WhitneyU test. (B) Histopathologic andmatrix-assisted laser desorption/ionization-
mass spectrometry imaging drug analysis on stereotactically registered specimens collected from a patient in cohort 1 treated with buparlisib. Image on the
left demonstrates location of buparlisib (green) and vessels as measured by heme (red). Hematoxylin and eosin (HE) staining of the corresponding tissue.
Outlined area delineates tumor and adjacent inﬁltrated brain parenchyma. (C) Representative microscopy images of the HE staining and PTEN, phos-
phorylated AKT (pAKT), and phosphorylated S6 (pS6) in tumor samples collected at baseline and on buparlisib treatment from a patient in cohort 1. (D)
Quantiﬁcation of pAKT immunohistochemistry (IHC) staining intensity in the surgical cohort. Data are mean6 SEM (n = 5 to 7 replicates for each sample). (E)
Box plots of mean pAKT IHC staining intensity in the archival and resected tissues from the surgical cohort (n = 14). Difference between groups was calculated
using the Wilcoxon test (See Appendix).
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Baseline characteristics of patients are listed in Table 1.
Sixty-four patients (98.5%) had received RT and temozo-
lomide, and 31 (41.7%) and eight (12.3%) had received
surgery or systemic therapy, respectively, for progressive
disease. Demonstration of PI3K pathway activation in ar-
chival tumor tissue was based on IHC of PTEN and
pAKTS473 status in 62 patients (95.4%) and genomic testing
in three (4.6%). Overall, 31 enrolled patients (47.7%) had
combined negative PTEN and positive pAKTS473 IHC; 24
(36.9%) had positive pAKTS473 IHC; seven (10.8%) had
negative PTEN IHC; and three (4.6%) had genomic testing
showing PTEN inactivation or PIK3CA mutation.
Pharmacokinetics and Pharmacodynamics of Buparlisib
Buparlisib was absorbed rapidly, achieving a maximum
plasma concentration of 4716 147 ng/mL and 8206 192
ng/mL within a median of 1.5 hours postdose on days 1 and
8, respectively (Appendix Table A2, online only). Both max-
imum plasma concentration and exposure (0- to 5-hour
area under the curve) increased between days 1 and 8,
with an accumulation ratio of 1.88 6 0.503 and 2.42 6
0.726, respectively (Appendix Table A2). The accumula-
tion of buparlisib was consistent with the reported half-life of
approximately 40 hours reaching steady state by day 8.17,18
Resected tumor tissue was evaluable for pharmacokinetics
and pharmacodynamics analyses in 14 patients. The av-
erage time between the last dose of buparlisib and the time
of tumor sampling was 56 1.61 hours. The average plasma
concentration at the time of the tumor sampling was
585 6 192 ng/mL. The geometric mean concentration of
buparlisib in the tumor tissue was 612 ng/g (range, 86 to
6,947 ng/g), with a resulting tumor-to-plasma geometric
mean ratio of 1.0 (range, 0.18 to 8.44). There was no
signiﬁcant difference between the non–contrast-enhancing
(CE) and CE tumor tissue concentrations of buparlisib
(mean, 4046 429 v 6546 363, respectively; P = 0.16; Fig
2A). Brain penetration of buparlisib also was conﬁrmed by
matrix-assisted laser desorption/ionization-mass spec-
trometry imaging performed on tumor specimens that
showed the presence of drug in the tumor as well as in the
inﬁltrated brain parenchyma (Fig 2B).
A decrease in pAKTS473 IHC score was achieved in six
patients (42.9%) and was statistically signiﬁcant in the
overall cohort (Figs 2C to 2E), whereas the analysis of an
independent set of pre- and post-treatment (RT + temo-
zolomide) glioblastoma pairs did not show signiﬁcant
change in pAKTS473 or pS6S235/236 IHC (Appendix Fig A2,
online only). A reduction in pAKTT308 only in post–buparlisib
treatment tumor also was observed in RPPA analysis of 299
antibodies (Appendix Table A4, online only). Nevertheless,
in seven patients (50%), no change in pAKTS473 IHC score
was noted, and one patient (7.1%) had an increase in
pAKTS473 IHC score, which suggested an incomplete
blockade of PI3K signaling in approximately one half of
patients. This ﬁnding was consistent with the absence of
modulation of pS6S235/236 by IHC and lack of consistent
changes in pS6S235/236, pS6S240/244, and p70 S6T389 kinases
in the RPPA analysis (Appendix Fig A3, online only; Ap-
pendix Table A4). Moreover, RPPA analysis did not show
a consistent change in members of the mitogen-activated
protein kinase (MAPK) pathway when comparing buparlisib-
treated versus control glioblastoma pairs (Appendix Table
A4). Finally, there was no signiﬁcant change in tumor cell
proliferation between baseline and post-buparlisib treat-
ment samples as assessed by the IHC proliferation marker
Ki-67 (Appendix Fig A2).
Outcome
At ﬁnal analysis (April 30, 2018), none of the 65 patients
remained on treatment. The most frequent reason for
treatment discontinuation in both groups was disease
progression (59 [90.8%]; Fig 1). The median follow-up was
15.6 months (range, 3.6 to 36.6 months) in cohort 1 versus
9.8 months (range, 1.0 to 71.2 months) in cohort 2.
The study did not meet its primary end point for PFS6 with
buparlisib in cohort 2 (n = 50); four patients (8%; 95% CI,
3% to 19%) reached PFS6, and the median PFS was
1.7 months (95% CI, 1.4 to 1.8 months; Table 2; Appendix
Fig A4, online only). OS data were mature, with 58 deaths in
the total population at the cutoff date (cohort 1, n = 13;
cohort 2, n = 45). Two patients were still alive, and ﬁve were
lost to follow-up. Themedian OS was 17.9months (95% CI,
TABLE 2. Response to Treatment
Response to Treatment
Response Cohort 1 (n 5 15) Cohort 2 (n 5 50)
Best response†, No (%)
CR 0 (0) 0 (0)
PR 0 (0) 0 (0)
SD 6 (40) 21 (42)
PD 9 (60) 27 (54)
Not evaluable 0 (0) 2 (4)
Disease control rate (CR, PR, or SD),
% (95% CI)†
40 (20 to 64) 43.8 (31 to 58)
PFS6 rate, % (95% CI)* 26.7 (11 to 52) 8 (3 to 19)
Median PFS, months (95% CI)‡ 1.8 (1.1 to 5.6) 1.7 (1.4 to 1.8)
Median OS, months (95% CI)§ 17.9 (9.3 to 29.2) 9.8 (8.4 to 12.1)
Abbreviations: CR, complete response; OS, overall survival; PD, progressive
disease; PR, partial response; PFS, progression-free survival; PFS6, 6-month
progression-free survival; SD, stable disease.
*Censored patients (two patients in cohort 2) were included in the calculations of
PFS6 proportions as patients not reaching PFS6.
†Assessed per Response Assessment in Neuro-Oncology.
‡Kaplan-Meier estimates; three patients from cohort 2 were censored without
having progressed.
§Kaplan-Meier estimate; two patients from cohort 1 were lost to follow-up, three
patients from cohort 2 were lost to follow-up, and two patients from cohort 2 were
still alive at data cutoff.
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9.3 to 29.2 months) in cohort 1 and 9.8 months (95% CI,
8.4 to 12.1 months) in cohort 2 (Table 2; Appendix Fig A4).
Best overall response was evaluable in 63 patients
(96.9%). No patients achieved a radiographic response
(Table 2). Six patients (40%; 95% CI, 20% to 64%) in
cohort 1 and 21 (43.8%; 95% CI, 31% to 58%) in cohort 2
had disease stabilization as best response. In addition, 12
patients in cohort 1 had an FDG-positron emission to-
mography scan performed before and after treatment with
buparlisib (mean delay, 11.4 days; range, 7 to 25 days). Six
of the 12 patients had a modest decrease in tumor-to-
background ratio in FDG uptake (22.35% to218.7%), but
there was no correlation with outcome.
Correlation of Outcomes With Genotyping
Correlation between outcome and tumor genotyping was
assessed in 46 patients (71.9%; eight [53.3%] in cohort 1
and 38 [76%] in cohort 2) for whom copy number array
and/or tumor-targeted sequencing was available (Fig 3).
Overall, pathogenic variants of PTEN, PIK3CA, or PIK3R1
were identiﬁed in 27 patients (56.3%; Fig 3).
Candidate biomarkers, including PTEN, PIK3CA, PIK3R1,
EGFR, PDGFRA, IDH1/2, and TP53 molecular alterations
and IHC evidence for PTEN inactivation, pAKTS473, and
pS6S235/236 activation, were evaluated for their association
with outcome. Although no statistically signiﬁcant associ-
ation was found between PFS6 or OS and any of the
candidate biomarkers, there was a shorter PFS in patients
with IDH1/2-mutant versus IDH1/2 wild-type glioblastoma
(median PFS, 0.9 months [interquartile range (IQR), 0.9-
1.8 months] v 1.8 months [IQR, 1.1-3.6 months], re-
spectively; log-rank P = .002; Appendix Fig A5, online only).
No statistically signiﬁcant association was found between
PFS and PIK3CA/PIK3R1-mutant glioblastoma (median
PFS, 2.2 months [IQR, 1.8-2.8 months] v 1.8 months [IQR,
0.9-2.8 months] in PIK3CA/PIK3R1 mutant v PIK3CA/
PIK3R1 wild type, respectively; log-rank P = .67) or PTEN
molecular alterations (median PFS, 1.8 months [IQR,
PTEN
p-AKT
p-S6
41.3%
95.7%
84.8%
OS
 24 months
12 months
0 months
 24 months
6 months
0 months
PFS
BOR
Cohort 1 Cohort 2
IHC expression
Positive
Negative
Wild type
Missense mutation
Truncating mutation
> 1 copy loss
Focal gain/amplification
Not available
Tumor genetic alteration
BOR
Stable disease
Progressive disease
Nonevaluable
CDKN2A/B
PTEN
EGFR
PDGFRA
MDM2
IDH1/2
TP53
PTEN
PIK3CA
PIK3R1
44.8%
24.1%
27.6%
20.7%
13.8%
19.6%
41.3%
32.6%
15.2%
4.3%
FIG 3. Relationship between mutations in phosphatidylinositol 3-kinase (PI3K) pathway members and response to buparlisib. Patient outcomes,
including best overall response (BOR), median progression-free survival (PFS), and median overall survival (OS), are shown in the top rows; tumor
genotyping and immunohistochemistry (IHC) results are shown in themiddle rows; and integrative biomarker analysis for PI3K/PTEN signaling is shown
in the bottom rows. Missense mutations are displayed in green, ampliﬁcations in orange, and deletions in blue. All mutations were reviewed by a
molecular diagnostician to conﬁrm that they were deemed pathogenic/hotspot mutations and were not commonly identiﬁed in normal databases as
germline single nucleotide polymorphisms.
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1.3-3.6 months] v 1.8 months [IQR, 0.9-2.8 months] in
PTEN mutant v PTEN wild type, respectively; log-rank P =
.57; Appendix Fig A5).
Toxicity
Table 3 lists the most common grade 3 and 4 adverse
events. Overall, grade 3 to 4 treatment-related adverse
events were reported in 40.0% (95% CI, 19.8% to 64.3%)
of patients in cohort 1 and 32.0% (95% CI, 20.8% to
45.8%) of patients in cohort 2. Only one patient (1.5%)
experienced a grade 4 toxicity that was at least possibly
related to treatment, and consisted of an asymptomatic
lipase increase. No suicidality was reported. No on-
treatment deaths occurred. Buparlisib treatment was dis-
continued in two patients (3.1%) as a result of adverse
events, one in each arm. Themost common adverse events
that led to dose reduction or discontinuation were in-
creased lipase in six patients (9.2%) and increased ALT
and hyperglycemia in ﬁve (7.7%).
DISCUSSION
This study shows that the brain-penetrant PI3K inhibitor
buparlisib hasminimal single-agent efﬁcacy in patients with
recurrent glioblastoma.5,20,21 Buparlisib did not meet the
primary pharmacodynamic and efﬁcacy end points of this
study. These ﬁndings are consistent with previous results
wherein PI3K/mTOR inhibitors alone or in combination with
cytotoxic or targeted therapies in patients with glioblastoma
unselected for PI3K pathway activation showed no clinical
beneﬁt.6,9-11,12,22-27 Although PI3K pathway activation was
conﬁrmed in all patients, post hoc analyses did not show a
correlation between the mutation status of PTEN, PIK3CA,
and PIK3R1 and outcome. Of note, a shorter PFS was
observed in patients with IDH1/2-mutant tumors. However,
because this was a post hoc analysis in a relatively small
number of patients with IDH1/2-mutant tumors, deﬁnitive
conclusions will require increased numbers.
To our knowledge, this study provides the ﬁrst evidence that
buparlisib can achieve adequate brain penetration in pa-
tients with glioblastoma. Buparlisib accumulation was seen
in both CE and non-CE areas of tumor, with a trend to higher
accumulation in CE areas. These ﬁndings are consistent
with preclinical and early-phase studies of buparlisib14,16,28,29
as well as with the phase III trial BELLE-2 in human epi-
dermal growth factor receptor 2–negative metastatic breast
cancer.30 In this study, a higher rate of psychiatric adverse
effects, including depression and anxiety, was observed
with buparlisib, which were not reported with other PI3K
inhibitors31-35 and were attributed to the high BBB pene-
tration of buparlisib.
Our multidimensional analysis, including IHC, study of cell
proliferation and signaling markers, RPPA, and tumor
genomic proﬁling provide important insights for un-
derstandingmechanisms of resistance to single-agent PI3K
inhibitors in glioblastoma. Although our analyses document
inhibition of pAKTS473 in a subset of patients, blockade of
the PI3K pathway activity was incomplete, as evidenced by
the limited effects on downstream pS6S235/236. This was
associated with minimal effects on tumor cell proliferation
and outcome. The morphometric IHC and RPPA analyses
suggest that persistent downstream signaling occured
through incomplete blockade of PI3K pathway together
with activity of complementary pathways, including MAPK
signaling. Previous studies showed that buparlisib con-
centrations required to fully inhibit PI3K activity generate
toxic off-target effects on cytoskeleton dynamics,36 which
suggests that the therapeutic window of buparlisib might be
too narrow in glioblastoma. The robust activity of PI3K
signaling in glioblastoma may require more potent and
selective inhibitors that would achieve greater pathway
inhibition without causing dose-limiting adverse events.
Besides incomplete PI3K pathway inhibition, the persistent
activity of p70 S6 kinases and the MAPK pathway observed
in the RPPA analysis suggests activation of alternate pro-
survival pathways that also may contribute to buparlisib
resistance. This phenomenon might be overcome by a
combination of buparlisib or other PI3K inhibitor with
inhibiting complementary signaling or feedback mole-
cules, such as sonic hedgehog, ribosomal S6 kinase, or
insulin.37-40
A limitation of our study was the use of historical data as
reference because of a lack of a control arm in the study
design. Nevertheless, the absence of radiologic response
TABLE 3. Summary of Grade 3 to 4 Treatment-Related Adverse Events
Adverse Event (CTCAE grade) No. (%)
Increased lipase (4) 1 (1.5)
Increased lipase (3) 6 (9.2)
Fatigue (3) 4 (6.2)
Increased ALT (3) 3 (4.6)
Hyperglycemia (3) 3 (4.6)
Hypophosphatemia (3) 2 (3.1)
Rash acneiform (3) 2 (3.1)
Rash maculopapular (3) 2 (3.1)
Diarrhea (3) 1 (1.5)
Increased AST (3) 1 (1.5)
Increased serum amylase (3) 1 (1.5)
Decreased lymphocyte count (3) 1 (1.5)
Decreased platelet count (3) 1 (1.5)
Anxiety (3) 1 (1.5)
Depression (3) 1 (1.5)
Photosensitivity (3) 1 (1.5)
Pruritus (3) 1 (1.5)
Conﬂuent erythema (3) 1 (1.5)
Abbreviation: CTCAE, Common Terminology Criteria for Adverse Events (version
4.0).
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observed in this study suggests that buparlisib has minimal
single-agent efﬁcacy in this population and is unlikely to
demonstrate beneﬁt against controls in future trials. An-
other limitation was that biomarker analyses for study entry
were performed on archival tissues instead of use of an
immediate pretreatment biopsy sample because the fea-
sibility of performing sequential biopsies was limited by
ethical considerations. However, recent studies that
addressed clonal evolution of glioblastoma under ther-
apy using whole-exome sequencing of pre- and post-
treatment–paired tumors showed that molecular alterations
of PTEN, PIK3CA, or PI3R1 are rarely lost in recurrent
samples.41-43 This suggests that although a certain de-
gree of clonal evolution occurs after treatment with DNA-
damaging agents, alterations in the PI3K pathway are likely
retained as targets in recurrent tumors in a majority of
patients.
In conclusion, this study shows that buparlisib does not
provide clinically meaningful beneﬁt in patients with PI3K-
activated recurrent glioblastoma. Our ﬁnding that pathway
inhibition was incomplete suggests that additional studies
are warranted to assess whether more potent and selective
PI3K inhibitors may achieve greater pathway inhibition and
clinical beneﬁt. Careful assessment of tissue pharmaco-
kinetics and pharmacodynamics through the surgical arm
of the study was important to our understanding that poor
pathway inhibition was likely the basis for the modest re-
sponse seen in patients. This suggests that in glioblastoma,
more routine use of studies speciﬁcally designed to conﬁrm
drug penetration and target engagement may be beneﬁcial
to perform before considering advancing a drug for more
testing. In addition, investigation of how PI3K inhibitors can
be combined with complementary therapeutics to provide
clinical beneﬁt in glioblastoma are still warranted and
should include studies designed to understand the de-
pendency and associations between biomarkers and re-
sponse to PI3K inhibitors, including PTEN, PIK3CA, PI3R1,
and IDH1/2 mutations.
AFFILIATIONS
1Dana-Farber Cancer Institute, Boston, MA
2Brigham and Women’s Hospital, Boston, MA
3Memorial Sloan Kettering Cancer Center, New York, NY
4The University of Texas M.D. Anderson Cancer Center, Houston, TX
5California Institute of Technology, Pasadena, CA
6David Geffen School of Medicine at University of California, Los Angeles,
Los Angeles, CA
7The University of Texas, San Antonio, San Antonio, TX
8Huntsman Cancer Institute and University of Utah, Salt Lake City, UT
9New York University School of Medicine, New York, NY
10Institute for Systems Biology, Seattle, WA
11Massachusetts General Hospital, Boston, MA
12University of California, San Francisco, San Francisco, CA
CORRESPONDING AUTHOR
Patrick Y. Wen, MD, Center for Neuro-Oncology, Dana Farber Cancer
Institute, 450 Brookline Ave, Dana 2-2202, Boston, MA 02215; Twitter:
@PatrickWen3; e-mail: pwen@partners.org
PRIOR PRESENTATION
Presented at the American Society of Clinical Oncology 2014 Annual
Meeting, Chicago, IL, May 30-June 3, 2014.
SUPPORT
Supported by the Ivy Foundation Early Phase Clinical Trials Consortium,
DFHCC/MIT Bridge Project (R01CA188288, P50 CA165962), and by
Novartis, which provided the drug and funding.
AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST
AND DATA AVAILABILITY STATEMENT
Disclosures provided by the authors and data availability statement (if
applicable) are available with this article at DOI https://doi.org/10.1200/
JCO.18.01207.
AUTHOR CONTRIBUTIONS
Conception and design: Patrick Y. Wen, Mehdi Touat, Shakti Ramkissoon,
Howard Colman, Eudocia Q. Lee, Susan M. Chang, Michael D. Prados,
W.K. Alfred Yung, Keith L. Ligon
Financial support: Keith L. Ligon
Administrative support: Christine S. McCluskey, Loreal E. Brown, W.K.
Alfred Yung
Provision of study material or patients: Patrick Y. Wen, Ingo K. Mellinghoff,
Howard Colman, Antonio M. Omuro, Lisa M. DeAngelis, Mark R. Gilbert,
John F. de Groot, Timothy F. Cloughesy, Eudocia Q. Lee, Lakshmi Nayak,
Tracy T. Batchelor, Susan M. Chang, Ian F. Dunn, Geoffrey S. Young,
Michael D. Prados, W.K. Alfred Yung, Keith L. Ligon
Collection and assembly of data: Patrick Y. Wen, Mehdi Touat, Ingo K.
Mellinghoff, Shakti Ramkissoon, Christine S. McCluskey, Kristine
Pelton, Sankha S. Basu, Sarah C. Gaffey, Loreal E. Brown, Jungwoo Kim,
Wei Wei, Mi-Ae Park, Jason T. Huse, Mikael L. Rinne, Howard Colman,
Nathalie Y.R. Agar, Antonio M. Omuro, Lisa M. DeAngelis, Mark R.
Gilbert, John F. de Groot, Andrew S. Chi, Eudocia Q. Lee, James R.
Heath, Laura L. Horky, Tracy T. Batchelor, Rameen Beroukhim, SusanM.
Chang, Ian F. Dunn, Dimpy Koul, Geoffrey S. Young, Michael D. Prados,
David A. Reardon, Keith L. Ligon
Data analysis and interpretation: Patrick Y. Wen, Mehdi Touat, Brian M.
Alexander, Ingo K. Mellinghoff, Shakti Ramkissoon, Kristine Pelton, Sam
Haidar, Sankha S. Basu, Juan Emmanuel Martinez-Ledesma, Shaofang
Wu, Wei Wei, Mi-Ae Park, John G. Kuhn, Nathalie Y.R. Agar, Antonio M.
Omuro, Lisa M. DeAngelis, Mark R. Gilbert, John F. de Groot, Timothy F.
Cloughesy, Thomas M. Roberts, Jean J. Zhao, Lakshmi Nayak, James R.
Heath, Laura L. Horky, Susan M. Chang, Azra H. Ligon, Dimpy Koul,
Michael D. Prados, Keith L. Ligon
Manuscript writing: All authors
Final approval of manuscript: All authors
Accountable for all aspects of the work: All authors
ACKNOWLEDGMENT
We thank the patients who took part in the study and their families as well
as the staff, research coordinators, and investigators at each participating
institution. We acknowledge the support of the Ben and Catherine Ivy
Foundation and Lisa Doherty, APRN, OCN; Debra Conrad LaFrankie, RN,
OCN; Sandra French Ruland, RN, BSN, OCN; Jennifer Stefanik, NP, and
Jann N. Sarkaria, MD, for sharing unpublished results. Finally, we
acknowledge the Center for Cancer Genome Discovery; Paul Van
Hummelen and Aaron Thorner; and the members of the Brigham and
Women’s Hospital Center for Advanced Molecular Diagnostics, Clinical
Cytogenetics Division.
748 © 2019 by American Society of Clinical Oncology Volume 37, Issue 9
Wen et al
REFERENCES
1. Ostrom QT, Gittleman H, Liao P, et al: CBTRUS statistical report: Primary brain and other central nervous system tumors diagnosed in the United States in 2010-
2014. Neuro-oncol 19:v1-v88, 2017
2. Wen PY, Kesari S: Malignant gliomas in adults. N Engl J Med 359:492-507, 2008
3. Stupp R, Hegi ME, Mason WP, et al: Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma
in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10:459-466, 2009
4. Stupp R, Taillibert S, Kanner AA, et al: Maintenance therapy with tumor-treating ﬁelds plus temozolomide vs temozolomide alone for glioblastoma: A ran-
domized clinical trial. JAMA 314:2535-2543, 2015
5. Touat M, Idbaih A, Sanson M, et al: Glioblastoma targeted therapy: Updated approaches from recent biological insights. Ann Oncol 28:1457-1472, 2017
6. Cloughesy TF, Yoshimoto K, Nghiemphu P, et al: Antitumor activity of rapamycin in a phase I trial for patients with recurrent PTEN-deﬁcient glioblastoma. PLoS
Med 5:e8, 2008
7. Hegi ME, Diserens AC, Bady P, et al: Pathway analysis of glioblastoma tissue after preoperative treatment with the EGFR tyrosine kinase inhibitor geﬁtinib--a
phase II trial. Mol Cancer Ther 10:1102-1112, 2011
8. Brennan CW, Verhaak RG, McKenna A, et al: The somatic genomic landscape of glioblastoma. Cell 155:462-477, 2013 [Erratum: Cell 157:753, 2014]
9. Wen PY, Lee EQ, Reardon DA, et al: Current clinical development of PI3K pathway inhibitors in glioblastoma. Neuro-oncol 14:819-829, 2012
10. Chang SM, Wen P, Cloughesy T, et al: Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Invest New Drugs 23:357-361, 2005
11. Ma DJ, Galanis E, Anderson SK, et al: A phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: NCCTG
N057K. Neuro-oncol 17:1261-1269, 2015
12. Pitz MW, Eisenhauer EA, MacNeil MV, et al: Phase II study of PX-866 in recurrent glioblastoma. Neuro-oncol 17:1270-1274, 2015
13. Burger MT, Pecchi S, Wagman A, et al: Identiﬁcation of NVP-BKM120 as a potent, selective, orally bioavailable class I PI3 kinase inhibitor for treating cancer.
ACS Med Chem Lett 2:774-779, 2011
14. Koul D, Fu J, Shen R, et al: Antitumor activity of NVP-BKM120--a selective pan class I PI3 kinase inhibitor showed differential forms of cell death based on p53
status of glioma cells. Clin Cancer Res 18:184-195, 2012
15. Maire CL, Ramkissoon S, Hayashi M, et al: Pten loss in Olig2 expressing neural progenitor cells and oligodendrocytes leads to interneuron dysplasia and
leukodystrophy. Stem Cells 32:313-326, 2014
16. Netland IA, Førde HE, Sleire L, et al: Treatment with the PI3K inhibitor buparlisib (NVP-BKM120) suppresses the growth of established patient-derived GBM
xenografts and prolongs survival in nude rats. J Neurooncol 129:57-66, 2016
17. Bendell JC, Rodon J, Burris HA, et al: Phase I, dose-escalation study of BKM120, an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors.
J Clin Oncol 30:282-290, 2012
18. Rodon J, Braña I, Siu LL, et al: Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-class I PI3K inhibitor, in patients with
advanced solid tumors. Invest New Drugs 32:670-681, 2014
19. Wen PY, Macdonald DR, Reardon DA, et al: Updated response assessment criteria for high-grade gliomas: Response assessment in Neuro-Oncology Working
Group. J Clin Oncol 28:1963-1972, 2010
20. Wong ET, Hess KR, Gleason MJ, et al: Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 17:
2572-2578, 1999
21. Lamborn KR, Yung WK, Chang SM, et al: Progression-free survival: An important end point in evaluating therapy for recurrent high-grade gliomas. Neuro-oncol
10:162-170, 2008
22. Wen PY, Chang SM, Lamborn KR, et al: Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor
Consortium trial 04-02. Neuro-oncol 16:567-578, 2014
23. Reardon DA, Quinn JA, Vredenburgh JJ, et al: Phase 1 trial of geﬁtinib plus sirolimus in adults with recurrent malignant glioma. Clin Cancer Res 12:860-868,
2006
24. Doherty L, Gigas DC, Kesari S, et al: Pilot study of the combination of EGFR and mTOR inhibitors in recurrent malignant gliomas. Neurology 67:156-158, 2006
25. Kreisl TN, Lassman AB, Mischel PS, et al: A pilot study of everolimus and geﬁtinib in the treatment of recurrent glioblastoma (GBM). J Neurooncol 92:99-105,
2009
26. Reardon DA, Desjardins A, Vredenburgh JJ, et al: Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma. J Neurooncol 96:219-230, 2010
27. Lassen U, SorensenM, Gaziel TB, et al: Phase II study of bevacizumab and temsirolimus combination therapy for recurrent glioblastomamultiforme. Anticancer
Res 33:1657-1660, 2013
28. Nanni P, Nicoletti G, Palladini A, et al: Multiorgan metastasis of human HER-2+ breast cancer in Rag2-/-;Il2rg-/- mice and treatment with PI3K inhibitor. PLoS
One 7:e39626, 2012
29. Maira M, Schnell C, Lollini P, et al: Preclinical and preliminary clinical activity of NVP-BKM120, an oral pan-class I PI3K inhibitor, in the brain. Ann Oncol 23,
2012 (suppl 9; abstr 1675P)
30. Baselga J, Im SA, Iwata H, et al: Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative,
advanced breast cancer (BELLE-2): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 18:904-916, 2017
31. Gopal AK, Kahl BS, de Vos S, et al: PI3Kd inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med 370:1008-1018, 2014
32. Saura C, Sachdev J, Patel MR, et al: Ph1b study of the PI3k inhibitor taselisib (GDC-0032) in combination with letrozole in patients with hormone receptor-
positive advanced breast cancer. Cancer Res 75, 2015 (suppl 9; abstr PD5-2)
33. Sarker D, Ang JE, Baird R, et al: First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in
patients with advanced solid tumors. Clin Cancer Res 21:77-86, 2015
34. Mayer IA, Abramson VG, Formisano L, et al: A phase Ib study of alpelisib (BYL719), a PI3Ka-speciﬁc inhibitor, with letrozole in ER+/HER2- metastatic breast
cancer. Clin Cancer Res 23:26-34, 2017
35. Dreyling M, Santoro A, Mollica L, et al: Copanlisib in patients with relapsed or refractory indolent B-cell lymphoma (Chronos-1). Hematol Oncol 35:119-120,
2017
36. Brachmann SM, Kleylein-Sohn J, Gaulis S, et al: Characterization of the mechanism of action of the pan class I PI3K inhibitor NVP-BKM120 across a broad
range of concentrations. Mol Cancer Ther 11:1747-1757, 2012
37. Filbin MG, Dabral SK, Pazyra-MurphyMF, et al: Coordinate activation of Shh and PI3K signaling in PTEN-deﬁcient glioblastoma: New therapeutic opportunities.
Nat Med 19:1518-1523, 2013
38. Serra V, Eichhorn PJ, Garcı´a-Garcı´a C, et al: RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer. J Clin Invest 123:2551-2563, 2013
Journal of Clinical Oncology 749
Buparlisib in Recurrent Glioblastoma With Activated PI3K Pathway
39. Hopkins B, Pauli C, Du X, et al: Suppression of insulin feedback enhances the efﬁcacy of PI3k inhibitors. Nature 560:499-503, 2018 [Erratum: Nature 563;E24,
2018]
40. Ni J, Ramkissoon SH, Xie S, et al: Combination inhibition of PI3K and mTORC1 yields durable remissions in mice bearing orthotopic patient-derived xenografts
of HER2-positive breast cancer brain metastases. Nat Med 22:723-726, 2016
41. Kim J, Lee IH, Cho HJ, et al: Spatiotemporal evolution of the primary glioblastoma genome. Cancer Cell 28:318-328, 2015
42. Kim H, Zheng S, Amini SS, et al: Whole-genome and multisector exome sequencing of primary and post-treatment glioblastoma reveals patterns of tumor
evolution. Genome Res 25:316-327, 2015
43. Wang J, Cazzato E, Ladewig E, et al: Clonal evolution of glioblastoma under therapy. Nat Genet 48:768-776, 2016
44. Louis DN, Ohgaki H, Wiestler OD, et al: World Health Organization Histological Classiﬁcation of Tumours of the Central Nervous System (ed 2). Lyon, France,
International Agency for Research on Cancer, 2016
45. Akbani R, Ng KS, Werner HMJ, et al: A pan-cancer proteomic perspective on the Cancer Genome Atlas Nature Comms: 5:3887, 2014
n n n
750 © 2019 by American Society of Clinical Oncology Volume 37, Issue 9
Wen et al
AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST
Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase
II Trial
The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held
unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about
ASCO’s conﬂict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/site/ifc.
Patrick Y. Wen
Honoraria: Merck
Consulting or Advisory Role: AbbVie, Agios Pharmaceuticals, AstraZeneca, Blue
Earth Diagnostics, Eli Lilly, Genentech, Roche, Immunomic Therapeutics,
Kadmon Corporation, KIYATEC, Puma Biotechnology, Vascular Biogenics, Taiho
Pharmaceutical, Deciphera Pharmaceuticals, VBI Vaccines
Speakers’ Bureau: Merck, prIme Oncology
Research Funding: Agios Pharmaceuticals (Inst), AstraZeneca (Inst), BeiGene
(Inst), Eli Lilly (Inst), Roche (Inst), Genentech (Inst), Karyopharm Therapeutics
(Inst), Kazia Therapeutics (Inst), MediciNova (Inst), Novartis (Inst), Oncoceutics
(Inst), Sanoﬁ (Inst), Aventis (Inst), VBI Vaccines (Inst)
Travel, Accommodations, Expenses: Merck
Mehdi Touat
Consulting or Advisory Role: Agios Pharmaceuticals, Taiho Pharmaceutical
Travel, Accommodations, Expenses: Merck Sharp & Dohme
Brian M. Alexander
Employment: Foundation Medicine
Ingo K. Mellinghoff
Honoraria: Roche
Consulting or Advisory Role: Agios Pharmaceuticals, Puma Biotechnology,
Debiopharm Group
Research Funding: General Electric, Amgen, Eli Lilly
Shakti Ramkissoon
Employment: Foundation Medicine
Stock and Other Ownership Interests: Foundation Medicine
Sam Haidar
Employment: Philips Healthcare
Stock and Other Ownership Interests: Johnson & Johnson
Wei Wei
Patents, Royalties, Other Intellectual Property: US patent application pending
from a technology related to health or medicine (application No. 15/045241)
Jason T. Huse
Employment: Champions Oncology
Research Funding: Taiho Pharmaceutical (Inst)
John G. Kuhn
Consulting or Advisory Role: TG Therapeutics
Research Funding: Methodist Health System
Mikael L. Rinne
Employment: Novartis Institutes for BioMedical Research
Consulting or Advisory Role: N-of-One
Howard Colman
Honoraria: Merck Sharp & Dohme
Consulting or Advisory Role: Novocure, AbbVie, Foundation Medicine, Innocrin
Pharmaceuticals, Tactical Therapeutics, Deciphera Pharmaceuticals, NewLink
Genetics, Best Doctors, Merck
Research Funding: NewLink Genetics, Plexxikon, Kadmon Corporation, Orbus
Therapeutics, Merck, DNAtrix, AbbVie, BeiGene, FORMA Therapeutics (Inst)
Nathalie Y.R. Agar
Consulting or Advisory Role: Bayesian Dx
Patents, Royalties, Other Intellectual Property: IP portfolio at Partners
Healthcare for surgical margin delineation and intraoperative diagnosis largely
based on mass spectrometry
Travel, Accommodations, Expenses: Bruker
Antonio M. Omuro
Consulting or Advisory Role: Stemline Therapeutics, Bristol-Myers Squibb,
Alexion Pharmaceuticals, Novocure, Inovio Pharmaceuticals
Lisa M. DeAngelis
Consulting or Advisory Role: Roche, CarThera, BMJ Publishing Group, BTG,
Tocagen, Sapience Therapeutics
John F. de Groot
Employment: Helsinn Therapeutics (I), Ziopharm Oncology (I)
Leadership: Ziopharm Oncology (I)
Stock and Other Ownership Interests: Gilead Sciences, Ziopharm Oncology (I)
Consulting or Advisory Role: Celldex, Deciphera Pharmaceuticals, Vascular
Biogenics, Foundation Medicine, Genentech, Roche, Omniox, OXiGENE,
AbbVie, Novogen, Kadmon Corporation, Merck, Five Prime Therapeutics, Insys
Therapeutics, AstraZeneca, Boston Biomedical, GW Pharmaceuticals, CarThera
Research Funding: Deciphera Pharmaceuticals, Novartis, Eli Lilly, Sanoﬁ, EMD
Serono, Mundipharma Aventis, AstraZeneca
Timothy F. Cloughesy
Stock and Other Ownership Interests: Notable Labs
Consulting or Advisory Role: Roche, Genentech, Celgene, Tocagen, VBL
Therapeutics, NewGen Therapeutics, Novartis, Agios Pharmaceuticals, Cortice
Biosciences, Novocure, AbbVie, OXiGENE, Wellcome Trust, Pﬁzer, Notable
Labs, Bristol-Myers Squibb, Merck, Insys Therapeutics, Human Longevity,
Sunovion, Boston Biomedical, Novogen, Alexion Pharmaceuticals, GW
Pharmaceuticals, Eli Lilly, Genocea Biosciences, Puma Biotechnology
Other Relationship: Global Coalition for Adaptive Research
Thomas M. Roberts
Leadership: iKang Healthcare Group, Geode Therapeutics, Crimson
Pharmaceutical
Stock and Other Ownership Interests: iKang Healthcare Group, Crimson
Pharmaceutical, Geode Therapeutics
Consulting or Advisory Role: Novartis Institutes for BioMedical Research
Patents, Royalties, Other Intellectual Property: Applied for patents combining
PI3K inhibitors with immunotherapies
Jean J. Zhao
Leadership: Crimson Pharmaceutical, Geode Therapeutics
Stock and Other Ownership Interests: Crimson Pharmaceutical, Geode
Therapeutics
Speakers’ Bureau: Ruijin Hospital
Research Funding: Eli Lilly, Puma Biotechnology
Patents, Royalties, Other Intellectual Property: Several intellectual properties at
Dana-Faber Cancer Institute as a co-inventor
Travel, Accommodations, Expenses: Ruijin Hospital, Princess Margaret Cancer
Centre
Eudocia Q. Lee
Honoraria: MedLink, UpToDate
Consulting or Advisory Role: Eli Lilly
Lakshmi Nayak
Honoraria: Bristol-Myers Squibb
Travel, Accommodations, Expenses: Bristol-Myers Squibb
James R. Heath
Leadership: Indi Molecular, PACT pharma, Soﬁe Biosciences, IsoPlexis,
Nirmidas Biotech, Arivale
Stock and Other Ownership Interests: Indi Molecular, IsoPlexis, PACT pharma
Tracy T. Batchelor
Honoraria: Champions Oncology, UpToDate, Imedex, NXDC, Merck,
GenomiCare Biotechnology
Consulting or Advisory Role:Merck, GenomiCare Biotechnology, NXDC, Amgen
Travel, Accommodations, Expenses: Merck, Roche, Genentech, GenomiCare
Biotechnology
Journal of Clinical Oncology
Buparlisib in Recurrent Glioblastoma With Activated PI3K Pathway
Rameen Beroukhim
Consulting or Advisory Role: Novartis, Merck (I), Gilead Sciences (I), ViiV
Healthcare (I)
Research Funding: Novartis
Patents, Royalties, Other Intellectual Property: Prognostic Marker for
Endometrial Carcinoma (US patent application 13/911456, ﬁled June 6, 2013),
SF3B1 Suppression as a Therapy for Tumors Harboring SF3B1 Copy Loss
(international application No. WO/2017/177191, PCT/US2017/026693, ﬁled
July 4, 2017), Compositions and Methods for Screening Pediatric Gliomas and
Methods of Treatment Thereof (international application No. WO/2017/132574,
PCT/US2017/015448, ﬁled 1/27/2017)
Susan M. Chang
Consulting or Advisory Role: Tocagen
Research Funding: Novartis (Inst), Agios Pharmaceuticals (Inst)
Azra H. Ligon
Leadership: Travera (I)
Stock and Other Ownership Interests: Travera (I)
Consulting or Advisory Role: Travera (I)
Geoffrey S. Young
Research Funding: Siemens Healthineers
Michael D. Prados
Stock and Other Ownership Interests: Quadriga BioSciences
Consulting or Advisory Role: Nativis, Tocagen
Research Funding: Genentech (Inst), Roche (Inst), Novartis (Inst), Nativis (Inst)
David A. Reardon
Honoraria: AbbVie, Cavion, Genentech, Roche, Merck, Midatech Pharma,
Momenta Pharmaceuticals, Novartis, Novocure, Regeneron Pharmaceuticals,
Stemline Therapeutics, Celldex, OXiGENE, Monteris Medical, Bristol-Myers
Squibb, Juno Therapeutics, Inovio Pharmaceuticals, Oncorus, Agenus, EMD
Serono, Merck, Merck KGaA, Taiho Pharmaceutical, Advantagene
Consulting or Advisory Role: Cavion, Genentech, Roche, Merck, Momenta
Pharmaceuticals, Novartis, Novocure, Regeneron Pharmaceuticals, Stemline
Therapeutics, Bristol-Myers Squibb, Inovio Pharmaceuticals, Juno
Therapeutics, Celldex, OXiGENE, Monteris Medical, Midatech Pharma,
Oncorus, AbbVie, Agenus, EMD Serono, Merck, Merck KGaA, Taiho
Pharmaceutical
Research Funding: Celldex (Inst), Incyte (Inst), Midatech Pharma (Inst), Tragara
Pharmaceuticals (Inst), Inovio Pharmaceuticals (Inst), Agenus (Inst), EMD
Serono (Inst), Acerta Pharma (Inst), Omnivox
W.K. Alfred Yung
Stock and Other Ownership Interests: DNATrix
Honoraria: DNAtrix, Amgen
Consulting or Advisory Role: DNAtrix, Boehringer Ingelheim
Patents, Royalties, Other Intellectual Property: DNATrix
Keith L. Ligon
Stock and Other Ownership Interests: Travera
Consulting or Advisory Role: Midatech Pharma, Bristol-Myers Squibb
Research Funding: Plexxikon (Inst), Amgen (Inst), X4 Pharmaceuticals (Inst),
Tragara Pharmaceuticals (Inst), Bristol-Myers Squibb (Inst), Eli Lilly (Inst)
Patents, Royalties, Other Intellectual Property: Molecular diagnostics assay
patent
No other potential conﬂicts of interest were reported.
© 2019 by American Society of Clinical Oncology Volume 37, Issue 9
Wen et al
APPENDIX Pharmacokinetic Evaluation
The analytic method for the quantitative determination of buparlisib in
human plasma and tumor was developed and validated by Novartis
(Basel, Switzerland). The method consists of a solid phase extraction
using a 96-well plate with Oasis HLB cartridge (10 mg, 30 mm; Waters,
Milford, MA) and analysis by liquid chromatography-tandem mass
spectrometry in multiple-reaction monitoring mode using electrospray
ionization in the positive ion mode. The method is suitable for the
determination of buparlisib in human plasma (EDTA) over the range of
1.00 ng/mL (lower limit of quantiﬁcation) to 1,000 ng/mL (upper limit of
quantiﬁcation). No matrix effect was observed; mean recovery ranged
from 59% to 61%. Buparlisib was stable in stock and diluted solutions,
in matrix, and after multiple freeze-thaw cycles. The assay method
exhibited sufﬁcient speciﬁcity and selectivity, accuracy, precision, and
sensitivity for the purposes and conclusions of the individual studies.
For pharmacokinetic studies, blood samples were collected at the
following time points on days 1 and 8 (6 1 day) before surgery: predose
and at 0.5, 1.5, 3, and 5 hours postdose. Non–contrast-enhancing and
contrast-enhancing brain tumor tissue and a concomitant blood
sample were obtained at the time of surgery. Standard pharmacoki-
netic parameters were determined using noncompartmental methods.
The tumor-to-plasma ratio was calculated by dividing the tumor
geometric mean concentration by the plasma geometric mean con-
centration at the time of surgery.
Immunohistochemical Studies
Immunohistochemical (IHC) stainings for PTEN (#9559, 1:50 dilution,
heated citrate retrieval; Cell Signaling Technologies, Danvers, MA),
positive phosphorylated AKT (pAKT) S473 (#4060, 1:75 dilution,
EDTA retrieval; Cell Signaling Technologies), and phosphorylated S6
(pS6) S235/236 (#4858, 1:75 dilution, EDTA retrieval; Cell Signaling
Technologies) were performed on 5-mm formalin-ﬁxed parafﬁn-
embedded (FFPE) tissue sections.
In the surgical component of the trial, modulation of the phospha-
tidylinositol 3-kinase pathway response in tumor tissue was de-
termined by pathologist-performed semiquantitative IHC scoring of
pAKT and pS6 on the basis of previously established methods in
preclinical models and clinical trials of glioblastoma.6,22 Sample
staining was scored for intensity in tumor cells on a 0 to 2+ scale (0,
no staining; 1+, weak positive staining; 2+, strong positive staining,
with 1+ and 2+ being the average intensity of all positive cells in the
cohort). Staining within nontumor elements (eg, macrophages,
vessels) was not included in the scoring. Change in pAKT and pS6
IHC scores was the difference in score from baseline to surgery in
each participant. Participants were classiﬁed into three groups; a
reduction of staining score of one or more degrees qualiﬁed for
response, whereas no change or an increase in score qualiﬁed for no
response.
Matrix-Assisted Laser Desorption/Ionization-Mass
Spectrometry Imaging Drug Analysis on Surgical
Specimens
Surgical sections were ﬂash frozen after surgery, stored at280°C, and
placed at225°C 1 hour before use. Twelve-micrometer coronal tissue
sections were prepared using a Microm HM550 cryostat (Thermo
Fisher Scientiﬁc, Waltham, MA) and thaw mounted onto indium
tinoxide–coated microscopic slides (Bruker, Billerica, MA) for matrix-
assisted laser desorption/ionization-mass spectrometry imaging and
onto optical slides for hematoxylin and eosin staining. Samples were
dried for 15 minutes in a desiccator. 2,5-Dihydroxybenzoic acid
(40 mg/mL solution in methanol OH/0.2% triﬂuoroacetic acid 70:30
volume-to-volume ratio) was deposited using the TM-Sprayer system
(HTX Technologies, Chapel Hill, NC) as previously described (Sun Y
et al: Neuro-oncol 19:774-785, 2017). Mass spectra were acquired
using a 9.4-T solariX XR Fourier transform ion cyclotron resonance
mass spectrometer (Bruker).
Tumor Genotyping
Targeted exome next-generation sequencing (OncoPanel) was per-
formed at the Dana-Farber Cancer Institute Center for Cancer Genome
Discovery on an approximately 50-mm thickness of FFPE tumor tissue
using the OncoPanel version 2.0 custom targeted exome capture panel
to examine the exons of 275 cancer-causing genes and their respective
single nucleotide variants and indels. Data were annotated as previously
described (Sholl LM, et al: JCI Insight 1:e87062, 2016; Ramkisson SH,
et al: Neuro-oncol 19:986-996, 2017). Array comparative genomic
hybridization copy number testing was performed using SurePrint G3
1M feature stock arrays (Agilent Technologies, Santa Clara, CA) from
approximately 1 mg of total DNA extracted from FFPE tissue (approxi-
mately 200-mm thickness of tissue) using fragmentation simulation
methodology (Craig JM, et al: PLoS One 7:e38881, 2012). Ampliﬁcation
was calculated as greater than 2.0 log-ratio, and single-copy losses
generally were calculated as less than20.3 log-ratio change compared
with a pooled DNA normal. Results were analyzed using CytoGenomics
and Genomic Workbench software (Agilent Technologies).
Reverse-Phase Protein Analysis
For comparison of signaling changes in buparlisib-treated patients, 11
paired untreated versus standard-of care–treated glioblastoma tumor
sets obtained from The University of Texas M.D. Anderson Cancer
Center were used as controls. Frozen tumor tissue approximately the size
of a grain of rice was placed in 2-mL tubes with ceramic beads using a
Precellys homogenizer (Bertin Instruments, Montigny-le-Bretonneux,
France). Tissue was lysed using ice-cold lysis solution. Lysates from
ﬂash-frozen tissues were prepared and analyzed by reverse-phase
protein analysis using 299 antibodies as described previously.45 Re-
verse phase protein microarrays were printed on nitrocellulose-coated
glass FAST Slides (Schleicher & Schuell BioScience, Keene, NH) by a
GeneTAC G3 arrayer (Genomic Solutions, Ann Arbor, MI). Antibody
staining of each reverse phase protein microarray was done using an
autostainer (BioGenex, Freemont, CA). The slide images were quantiﬁed
using MicroVigene 4.0 (VigeneTech, Carlisle, MA). The spot-level raw
data were processed using the R package SuperCurve (https://r-forge.
r-project.org/R/?group_id=1899), which returns the estimated protein
concentrations (raw concentration) and a quality control score for each
slide. Raw concentration data were normalized by median centering of
each sample across all proteins to correct loading bias.
Statistical Analyses
Data were summarized as frequencies and proportions for categorical
variables and as medians and ranges for continuous variables.
Intrapatient mean differences were evaluated with the paired Wilcoxon
test. Intercohort mean differences were evaluated with the Mann-
Whitney U test. Survival analyses (ie, progression-free survival [PFS],
overall survival) were performed using the Kaplan-Meier method, and
differences between groups were evaluated by the log-rank test.
Survival for participants who were alive or lost to follow-up at the time of
last contact on or before data cutoff was censored at the date of the last
contact alive. Patients who were censored for PFS before 6-month PFS
(PFS6) determination were included in the calculation of the PFS6
proportion as patients who did not reach PFS6. For biomarker eval-
uation, categorical groups were explored while considering variable
distribution to evaluate the possible association with outcome using the
Fisher’s exact test (PFS6) or the log-rank test (PFS, overall survival).
Differentially expressed proteins in pre- and post-treatment samples
were determined using Limma (Ritchie ME, et al: Nucleic Acids Res
43:e47, 2015), a software package used to perform differential ex-
pression analysis, and the R language (http://www.R-project.org). P =
.05 was set for statistical signiﬁcance for all evaluations.
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FIG A1. Treatment schema. CR, complete response; GBM, glioblastoma; IHC, immunohistochemistry; MRI, magnetic resonance imaging; pAKT,
phosphorylated AKT; PD, progressive disease; PI3K, phosphatidylinositol 3-kinase; PR, partial response; SD, stable disease.
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FIG A2. Phosphatidylinositol 3-kinase pathway modulation as a result of buparlisib in tumor tissue in the control
cohort. Quantiﬁcation of (A and B) phosphorylated AKTS473 (pAKTS473) and (C and D) phosphorylated S6 S235/
236 (pS6S235/236) immunohistochemistry staining in the surgical cohort. The control cohort consisted of seven
patients treated with standard of care for whom surgical resection of tumor tissue was performed at initial
diagnosis and recurrence. (B andD) Differences between groups were calculated using the pairedWilcoxon test.
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FIG A3. Phosphatidylinositol 3-kinase pathway modulation and changes in tumor cell proliferation as a result of
buparlisib in tumor tissue in cohort 1. (A and B) Quantiﬁcation of phosphorylated S6 S235/236 (pS6S235/236)
immunohistochemistry staining and (C and D) tumor cell proliferation as assessed by the IHC proliferation marker
Ki-67 in the surgical cohort. (B and D) Differences between groups were calculated using the paired Wilcoxon test.
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FIG A5. Kaplan-Meier curves of overall survival (OS) and progression-free survival (PFS) by (A and B) IDH1/2 status, (C and D) PIK3CA/PIK3R1
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TABLE A1. Summary of the Response Assessment in Neuro-Oncology Response Criteria
Assessment CR PR SD PD
T1 Gd+ None $ 50% decrease , 50% decrease to , 25% increase $ 25% increase*
T2/FLAIR Stable or decrease Stable or decrease Stable or decrease Increase*
New lesion None None None Present*
Corticosteroids None Stable or decrease Stable or decrease NA
Clinical status Stable or increase Stable or increase Stable or increase Decrease*
Requirement for response All All All Any*
Abbreviations: CR, complete response; NA, not applicable (increase in corticosteroids alone will not be taken into account in determining progression in the
absence of persistent clinical deterioration); PD, progressive disease; PR, partial response; SD, stable disease; T1 Gd+, gadolinium-enhancing lesion on T1
magnetic resonance imaging; T2/FLAIR, ﬂuid-attenuated inversion recovery on T2 magnetic resonance imaging.
*Progression occurs when criterion is present.
TABLE A2. Buparlisib Pharmacokinetic Parameters
Day Cmax (ng/mL), Mean 6 SEM Tmax (h), Median (range)
AUC0-5 h (mg $ h/mL),
Mean 6 SEM
1 471 6 147 1.5 (1.5-5) 1.42 6 0.5
8 820 6 192 1.5 (0.5-9) 3.27 6 1.43
Abbreviations: AUC0-5 h, 0- to 5-hour area under the curve; Cmax, maximum plasma concentration; Tmax, maximum time.
TABLE A3. Buparlisib Pharmacokinetic Parameters in Cohort 1
Cohort 1 (n = 15)
Time (hours) Presurgery Concentration (ng/mL)* Range
Predose 426 6 160 203-746
0.5 507 6 218 252-948
1.5 705 6 301 281-1,300
3 676 6 218 408-1,290
5 623 6 244 397-1,030
*Patients in the surgical cohort had presurgery sampling performed after 5 to 9 days of treatment with buparlisib.
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TABLE A4. Reverse-Phase Protein Array Analysis of Buparlisib-Treated Contrast-Enhancing Tumors Versus Unrelated SOC-Treated Control Tumors
Protein Symbol Buparlisib Treated SOC Treated P
Cyclin-E1-M-V CCNE1 0.1172 20.0771 .0029
Mcl-1-R-V MCL1 0.2553 20.2491 .0069
Cyclin-B1-R-V CCNB1 0.3047 20.2241 .0168
RPA32-T-C RPA2 0.0824 20.1633 .0194
D-a-Tubulin-R-V TUBA1A 20.5775 0.0379 .0208
Akt_pT308-R-V AKT1 20.2614 0.0723 .0219
Connexin-43-R-C CNST43 21.1597 0.3410 .0244
eIF4G-R-C EIF4G1 0.3188 20.3195 .0340
HSP27_pS82-R-V HSBP1 0.2195 20.2570 .0371
Rb_pS807_S811-R-V RB1 20.5456 0.1168 .0401
Annexin-I-M-V ANXA1 0.6267 20.1652 .0403
Hif-1-alpha-M-C HIF1A 20.0044 0.1676 .0444
JNK2-R-C MAPK9 20.0820 0.0755 .0619
p38-MAPK-R-V MAPK14 0.2682 20.2081 .0622
p38_pT180_Y182-R-V MAPK14 20.3590 20.0877 .2718
MAPK_pT202_Y204-R-V MAPK3 20.1771 0.1634 .0850
p44-42-MAPK-R-V MAPK3 20.2158 20.1204 .6713
JNK_pT183_Y185-R-V MAPK8 0.1351 0.0227 .3315
MEK1-R-V MAP2K1 20.3323 20.1404 .4235
MEK1_pS217_S221-R-V MAP2K1 20.0759 20.0575 .7944
RSK-R-C RPS6KA1 20.2927 20.0392 .1175
p70-S6K_pT389-R-V RPS6KB1 20.0628 20.1197 .8281
S6_pS235_S236-R-V RPS6 0.1864 20.2722 .1689
S6_pS240_S244-R-V RPS6 0.0869 20.2706 .2182
S6-M-V RPS6 0.1897 20.1757 .3136
p90RSK_pT573-R-C RPS6K 20.0128 20.0574 .8178
Akt_pS473-R-V AKT1 20.3848 0.0711 .2000
NOTE. Differences in pre- and post-treatment protein expression in each group were evaluated using Limma (Ritchie ME, et al: Nucleic Acids Res 43:e47,
2015). Selected proteins and proteins that showed statistically signiﬁcant changes between buparlisib-treated (contrast-enhancing regions) and unrelated
control tumors that underwent SOC (radiation therapy and temozolomide) are shown.
Abbreviation: SOC, standard of care.
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